Literature DB >> 18000220

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

Sarah Gould1, F Russell Westwood, Jon O Curwen, Susan E Ashton, David W Roberts, Susan C Lovick, Anderson J Ryan.   

Abstract

Antivascular agents that act by destabilizing microtubules, such as ZD6126 (N-acetylcolchinol-O-phosphate), are associated with adverse cardiovascular effects, including transient hypertension, cardiac ischemia, myocardial infarction, and increases in circulating levels of markers of cardiac damage (e.g., troponins). We investigated mechanisms underlying these effects of ZD6126 in rats by continuously monitoring their heart rate and blood pressure and by assessing heart histopathology and plasma troponin T levels. ZD6126 induced acute transient hemodynamic changes (hypertension and delayed tachycardia), which were associated with statistically significant increases in circulating troponin T levels (median level 3 hours after treatment with vehicle or 12.5 mg/kg ZD6126: <9 pg/mL and 563 pg/mL, respectively; P <.001 [two-sided Wilcoxon rank sum test]) and in the incidence of left ventricular myocardial fiber necrosis (incidence 24 hours after treatment with vehicle or 12.5 mg/kg ZD6126: 0/10 rats and 9/10 rats, respectively; P <.001 [two-sided Wilcoxon rank sum test]). Pretreatment of rats with atenolol and nifedipine ameliorated the acute hemodynamic changes and prevented ZD6126-induced increases in both troponin T and myocardial necrosis but did not prevent ZD6126-induced tumor necrosis in an Hras5 tumor xenograft model in nude rats. Our findings suggest that ZD6126-induced acute hemodynamic changes are a prerequisite for cardiac damage in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000220     DOI: 10.1093/jnci/djm202

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

Review 1.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

Review 2.  An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Authors:  Marlein Miranda Cona; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  World J Methodol       Date:  2013-12-26

Review 3.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

4.  Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.

Authors:  Patricia M LoRusso; Shirish M Gadgeel; Antoinette Wozniak; Alan J Barge; Helen K Jones; Zachary S DelProposto; Pamela A DeLuca; Jeffrey L Evelhoch; Scott A Boerner; Catherine Wheeler
Journal:  Invest New Drugs       Date:  2008-01-25       Impact factor: 3.850

5.  A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.

Authors:  Anne M Traynor; Michael S Gordon; Dona Alberti; David S Mendelson; Mark S Munsey; George Wilding; Richard E Gammans; William L Read
Journal:  Invest New Drugs       Date:  2009-05-13       Impact factor: 3.850

6.  Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Authors:  M H A M Fens; K J Hill; J Issa; S E Ashton; F R Westwood; D C Blakey; G Storm; A J Ryan; R M Schiffelers
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

Review 7.  Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.

Authors:  Rachel Grisham; Bonnie Ky; Krishnansu S Tewari; David J Chaplin; Joan Walker
Journal:  Gynecol Oncol Res Pract       Date:  2018-01-05

8.  Structure-Based Pharmacophore Design and Virtual Screening for Novel Tubulin Inhibitors with Potential Anticancer Activity.

Authors:  Yunjiang Zhou; Bin Di; Miao-Miao Niu
Journal:  Molecules       Date:  2019-09-01       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.